Microport
Microport
Microport mainly engages in medical research and medical equipment production.
MicroPort, established in 1998, is a medical device manufacturer. The company's products cover ten major fields, such as implants, orthopedic medical devices, aortic and puncture vascular intervention products, electrophysiological medical devices and nerve implant products. Founded by Chang Yaohua, it went public on the Hong Kong Stock Exchange. The shareholders are Otsuka, Maxwell Maxcare Science, Shanghai ZJ Hi-Tech Investment, Starwick Investments. Microport's direct competitors include Lepu Medical and Weigao.
- All
- News
- Analysis
- Research
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
In-depth
Healthcare
BeiGene: a Vast Opportunity Lies Ahead – But We Remain Cautious
BeiGene, a leader in China's novel pharmaceutical industry, recently received approval in Kuwait, Bahrain, and Qatar for its medication BRUKINSA (zanubrutinib). Previous contracts with major biopharma have produced substantial licensing income, but they did not lessen BeiGene's financial burden.
Jun 24, 2022 12:13 PM
Briefing Jun 24, 2022 10:46 AM
· Healthcare
East China medicine "liraglutide" goes to sea
Apr 22, 2021 03:11 PM
Research
Technology, Healthcare, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Aug 09, 2020 12:23 AM
Briefing Jun 23, 2022 06:25 PM
· Healthcare
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Briefing Jun 23, 2022 06:24 PM
· Healthcare
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Briefing Jun 23, 2022 10:36 AM
· Healthcare
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Briefing Jun 23, 2022 10:27 AM
· Healthcare
Yanye new crown drug 3CL protein inhibitor has been suspended approval
Healthcare
NK Celltech Receives a Series A Round of Funding Worth More Than CNY 100 Million
NK Celltech recently received a Series A round of funding totaling more than CNY 100 million. Huagai Capital led this round of funding, which was followed by CASVC, Unifortune, 呈益资本, Sirius Capital, and QJ Capital.
Jul 01, 2022 03:58 PM
Briefing Jun 23, 2022 10:24 AM
· Healthcare
Sanofi Greater China will be headed by Shi Wang, and Henting he will become the global head of the digital business unit
Briefing Jun 23, 2022 10:22 AM
· Healthcare
Acadia Alzheimer's drug SNDA application rejected by FDA advisory committee
Briefing Dec 28, 2021 11:59 PM
· Healthcare
Minimally invasive medicine proposes to spin off minimally invasive brain science and list it independently on the main board of the stock exchange
Briefing Oct 30, 2021 10:44 AM
· Healthcare
Minimally invasive group investment holding Argus strengthens the multi-dimensional layout of precision medicine in the pan vascular field
Briefing Dec 11, 2020 09:57 PM
· Healthcare
Minimally invasive medical treatment: considering the separation of minimally invasive medical robot and independent listing
See more
Related Companies
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.